VIDEO: Anti-VEGF agents for pigment epithelial detachment may increase atrophy risk
Click Here to Manage Email Alerts
BARCELONA, Spain — In this Healio Video Perspective from the Euretina meeting, Francesco Boscia, MD, discusses the role of new anti-VEGF agents in the treatment of pigment epithelial detachment.
Management of pigment epithelial detachments (PEDs) poses significant challenges because they are usually more resistant to compartmentalization of fluid within the retina, he explained.
Newer, more potent agents — brolucizumab, faricimab and aflibercept 8 mg — may lead to faster PED reabsorption but also increased risk for atrophy and visual acuity loss.
“The challenge is to achieve that resolution of fluid compartmentalized underneath the pigment epithelium without causing deterioration of visual acuity,” Boscia said.
Collapse
Boscia F. New-generation anti-VEGF agents are specifically beneficial for pigment epithelial detachment – Against. Presented at: Euretina congress; Sept. 18-22, 2024; Barcelona, Spain.
Read more about
Click Here to Manage Email Alerts